Corrigendum to "Acute hepatitis caused by a natural lipid-lowering product: When "alternative" medicine is no "alternative" at all" [J Hepatol 50 (2009) 1273-1277] (DOI:10.1016/j.jhep.2009.02.021);Acute hepatitis caused by a natural lipid-lowering product: When "alternative" medicine is no "alternative" at all

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1273-1277

  Grieco, Antonio ^a   Miele, Luca ^a   Pompili, Maurizio ^a   Biolato, Marco ^a   Vecchio, Fabio M ^a   Grattagliano, Ignazio ^b   Gasbarrini, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Alternative medicine; Drug induced liver disease; Equisterol; Hepatotoxicity; Lovastatin; Red yeast rice

Indexed keywords

ANTILIPEMIC AGENT; EQUISTEROL; GLUTATHIONE; GUGGULSTERONE; HERBACEOUS AGENT; MEVINOLIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; XUEZHIKANG;

ACUTE HEPATITIS; ADULT; ALTERNATIVE MEDICINE; ANTIBODY TITER; ARTICLE; CASE REPORT; DOPPLER FLOWMETRY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TOXICITY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL;

EID: 67349157709     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.10.032     Document Type: Erratum

References (28)

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
2. Khorashadi S., Hasson N., and Cheung R. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 4 (2006) 902-907
3. de Denus S., Spinler S., Miller K., and Peterson A. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 24 (2004) 584-591
4. Silva M., Swanson A., Gandhi P., and Tataronis G. Statin-related adverse events: a meta-analysis. Clin Ther 28 (2006) 26-35
5. Pfeffer M., Keech A., Sacks F., Cobbe S., Tonkin A., Byington R., et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 105 (2002) 2341-2346
6. Lewis J., Mortensen M., Zweig S., Fusco M., Medoff J., and Belder R. Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46 (2007) 1453-1463
7. Elinav E., Pinsker G., Safadi R., Pappo O., Bromberg M., Anis E., et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 47 (2007) 514-520
8. Schoepfer A., Engel A., Fattinger K., Marbet U., Criblez D., Reichen J., et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 47 (2007) 521-526
9. Miele L., Vero V., Gasbarrini G., and Grieco A. Braised liver with herbs: the risks of naturopathic hepatoprotection. J Clin Gastroenterol 39 (2005) 344
10. Urizar N., Liverman A., Dodds D., Silva F., Ordentlich P., Yan Y., et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296 (2002) 1703-1706
11. Bianchi A., Cantù P., Firenzuoli F., Mazzanti G., Menniti-Ippolito F., and Raschetti R. Rhabdomyolysis caused by Commiphora mukul, a natural lipid-lowering agent. Ann Pharmacother 38 (2004) 1222-1225
12. Zhu Y., Li C., Wang Y., Zhu J., Chang J., and Kritchevsky D. Monascus purpureus (red yeast): a natural product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutr Res 18 (1998) 71-81
13. Heber D., Yip I., Ashley J., Elashoff D., Elashoff R., and Go V. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69 (1999) 231-236
14. Prasad G., Wong T., Meliton G., and Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 74 (2002) 1200-1201
15. Havel R. Dietary supplement or drug? The case of cholestin. Am J Clin Nutr 69 (1999) 175-176
16. Endo A. The origin of the statins. Atheroscler Suppl 5 (2004) 125-130
17. Shapiro M., and Lewis J. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 11 (2007) 477-505
18. Roselle H., Ekatan A., Tzeng J., Sapienza M., and Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med 149 (2008) 516-517
19. Vuppalanchi R., Teal E., and Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 329 (2005) 62-65
20. Grimbert S., Pessayre D., Degott C., and Benhamou J. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 39 (1994) 2032-2033
21. Tolman K. The liver and lovastatin. Am J Cardiol 89 (2002) 1374-1380
22. Graziadei I., Obermoser G., Sepp N., Erhart K., and Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12 (2003) 409-412
23. Pelli N., Setti M., Ceppa P., Toncini C., and Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 15 (2003) 921-924
24. Alla V., Abraham J., Siddiqui J., Raina D., Wu G., Chalasani N., et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 40 (2006) 757-761
25. Alvarez F., Berg P., Bianchi F., Bianchi L., Burroughs A., Cancado E., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
26. Saper R.B., Phillips R.S., Sehgal A., Khouri N., Davis R.B., Paquin J., et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold over the internet. JAMA 300 (2008) 915-923
27. Lin J.L., Lin-Tan D.T., Hsu K.H., and Yu C.C. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 348 (2003) 277-286
28. Canfield R.L., Henderson Jr. C.R., Cory-Slechta D.A., Cox C., Jusko T.A., and Lanphear B.P. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 348 (2003) 1517-1526